Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: Pooled analysis of a clinical trial extension

Annals of General Psychiatry

Volumn 9, Issue , 2010, Pages

  Kozma, Chris M ^a   Dirani, Riad G ^b   Canuso, Carla M ^b   Mao, Lian ^b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIPERIDONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL ASSESSMENT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PERSONAL AND SOCIAL PERFORMANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHIZOPHRENIA; SYMPTOM;

EID: 77952819210     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-9-24     Document Type: Article

References (20)

1. Kay SR, Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
2. PubMed citation page for Kay et al. , http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/3616518/citedby/?tool=pubmed
3. Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007, 27:6-14. 10.1097/JCP.0b013e31802dda4a, 17224706.
4. Juckel G, Morosini PL. The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Curr Opin Psychiatry 2008, 21:630-639. 10.1097/YCO.0b013e328314e144, 18852573.
5. Bellack AS, Green MF, Cook JA, Fenton W, Harvey PD, Heaton RK, Laughren T, Leon AC, Mayo DJ, Patrick DL, Patterson TL, Rose A, Stover E, Wykes T. Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on a NIMG-sponsored workshop. Schizophrenia Bull 2007, 33:805-822.
6. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000, 101:323-329.
7. PubMed citation page for Morosini et al. , http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/10782554/citedby/?tool=pubmed
8. Patrick DL, Burns T, Morosini P, Rothman M, Gagnon DD, Wild D, Adriaenssen I. Reliability, validity and ability to detect change of clinician-rated personal and social performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin 2009, 25:325-338. 10.1185/03007990802611919, 19192977.
9. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psych 2005, 162:441-449.
10. Dirani R, Kozma C, Mao L, Amatniek J, Canuso C. Relationship between function and employment status in patients with schizophrenia. Poster presented at The College of Psychiatric and Neurologic Pharmacists (CPNP) Annual Meeting: 13-16 April 2008; Scottsdale, AZ, USA
11. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res 2004, 67:131-42. 10.1016/S0920-9964(03)00192-0, 14984872.
12. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell'Olio M, Francey SM, Cosgrave EM, Killackey E, Stanford C, Godfrey K, Buckby J. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust NZ J Psychiatry 2005, 39:964-971.
13. Schafer MR, Klier CM, Papageorgiou K, Friedrich MH, Amminger GP. Early detection of psychotic disorders [in German]. Neuropsychiatr 2007, 21:37-44.
14. Cougnard A, Goumilloux R, Monello F, Verdoux H. Time between schizophrenia onset and first request for disability status in France and associated patient characteristics. Psychiatr Serv 2007, 58:1427-1432. 10.1176/appi.ps.58.11.1427, 17978252.
15. Janicak PG, Wu JH, Mal L. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials. Curr Med Res Opin 2008, 24:1807-1815. 10.1185/03007990802119368, 18559166.
16. Kozma C, Dirani R, Mao L, Amatniek J, Canuso C. Change in employment status over 52 weeks in patients with schizophrenia. Poster presented at The American Psychiatric Association (APA) 161st Annual Meeting; Washington, DC, USA 2008,
17. Eerdekens M, Kramer M, Lane R, Lim P, Martinez L, Canuso C. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52 week, open-label extension studies. Poster presented at The International Congress on Schizophrenia Research 2007, Colorado Springs, CO, USA.
18. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007, 62:1363-1370. 10.1016/j.biopsych.2007.01.017, 17601495.
19. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007, 90:147-161. 10.1016/j.schres.2006.09.012, 17092691.
20. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6 week, placebo-controlled studies. J Clin Psychiatry 2008, (69):817-829. 10.4088/JCP.v69n0515, 18466043.